

The management of diabetic retinopathy without laser

By Jonathan Dowler

References

1. Kelly WF, Anapliotou M, Joplin GF. Pituitary ablation and its effect on diabetic retinopathy. *International ophthalmology clinics*. 1978 Jan 1;18(4):165-78.
2. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. *Ophthalmology*. 1981 Jul 1;88(7):583-600.
3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. *Arch Ophthalmol*. 1985 Dec 1;103(12):1796-806.
4. The St Vincent Declaration. 1989 Jan 1:1-2.
5. Dowler JG, Sehmi KS, Hykin PG, Hamilton AM. The natural history of macular edema after cataract surgery in diabetes. *Ophthalmology*. 1999 Apr 1;106(4):663-8.
6. Hykin PG, Gregson RM, Stevens JD, Hamilton PA. Extracapsular cataract extraction in proliferative diabetic retinopathy. *Ophthalmology*. 1993 Mar 1;100(3):394-9.
7. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy. *Retina*. 2007 Sep 1;27(7):816-24.
8. Vernon SA, Bhagey J, Boraik M, El-Defrawy H. Long-term review of driving potential following bilateral panretinal photocoagulation for proliferative diabetic retinopathy. *Diabet Med*. 2009 Jan 1;26(1):97-9.
9. Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M. Quantifying alterations of macular thickness before and after panretinal

photocoagulation in patients with severe diabetic retinopathy and good vision. *Ophthalmology*. 2003 Dec 1;110(12):2386-94.

10. Greenstein VC, Chen H, Hood DC, Holopigian K, Seiple W, Carr RE. Retinal function in diabetic macular edema after focal laser photocoagulation. *Investigative Ophthalmology & Visual Science*. 2000 Oct 1;41(11):3655-64.

11. Wallow IH, Bindley CD. Focal photocoagulation of diabetic macular edema. A clinicopathologic case report. *Retina (Philadelphia, Pa)*. 1988 Jan 1;8(4):261-9.

12. Browning DJ, Zhang Z, Benfield JM, Scott AQ. The effect of patient characteristics on response to focal laser treatment for diabetic macular edema. *Ophthalmology*. 1997 Mar 1;104(3):466-72.

13. Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. *Retina (Philadelphia, Pa)*. 2009 May 1;29(5):601-5.

14. Doft BH, Wisniewski SR, Kelsey SF, Fitzgerald SG, Group EVS. Diabetes and postoperative endophthalmitis in the endophthalmitis vitrectomy study. *Arch Ophthalmol*. 2001 May 1;119(5):650-6.

15. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. *J Exp Med*. 2003 Aug 4;198(3):483-9.

16. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Luttjans GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. *American Journal of Ophthalmology*. 2002 Mar 1;133(3):373-85.

17. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. *Arch Ophthalmol*. 1996 Jan 1;114(1):66-71.

18. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. *Proc Natl Acad Sci USA*. 1995 Nov 7;92(23):10457-61.

19. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med*. 1994 Dec 1;331(22):1480-7.
20. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the pathogenesis of diabetic retinopathy. *Expert Opin Investig Drugs*. 2004 Oct 1;13(10):1275-93.
21. Nishijima K, Ng Y-S, Zhong L, Bradley J, Schubert W, Jo N, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. *Am J Pathol*. 2007 Jul 1;171(1):53-67.
22. Scappaticci FA, Skillings JR, Holden SN, Gerber H-P, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. *J Natl Cancer Inst*. 2007 Aug 15;99(16):1232-9.
23. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. *Ophthalmology*. 2009 Sep 1;116(9):1731-9.
24. Cunningham ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. *Ophthalmology*. 2005 Oct 1;112(10):1747-57.
25. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. *Ophthalmology*. 2006 Oct 1;113(10):1706-12.
26. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. *American Journal of Ophthalmology*. 2006 Dec 1;142(6):961-9.
27. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. *Ophthalmology*. 2009 Nov

1;116(11):2175-81.e1.

28. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. *Retina (Philadelphia, Pa)*. 2006 Jan 1;26(9):999-1005.

29. Arevalo JF, Garcia-Amaris RA, Roca JA, Sanchez JG, Wu L, Berrocal MH, et al. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. *Journal of cataract and refractive surgery*. 2007 Dec 1;33(12):2098-105.

30. Diabetic Retinopathy Clinical Research Group, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. *Ophthalmology*. 2007 Oct 1;114(10):1860-7.

31. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. *Retina (Philadelphia, Pa)*. 2008 Oct 1;28(8):1053-60.

32. Adamis AP, Altaweel M, Bressler NM, Cunningham ET, Davis MD, Goldbaum M, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. *Ophthalmology*. 2006 Jan 1;113(1):23-8.

33. González VH, Giuliari GP, Banda RM, Guel DA. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. *Br J Ophthalmol*. 2009 Nov 1;93(11):1474-8.

34. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. *Retina (Philadelphia, Pa)*. 2006 Mar 1;26(3):352-4.

35. Arevalo JF, Wu L, Sanchez JG, Maia M, Saravia MJ, Fernandez CF, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. *Eye*. 2009 Jan 1;23(1):117-23.

36. Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. *Graefes Arch Clin Exp Ophthalmol*. 2008 Dec

1;246(12):1699-705.

37. Tonello M, Costa RA, Almeida FPP, Barbosa JC, Scott IU, Jorge R. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). *Acta Ophthalmologica*. 2008 Jun 1;86(4):385-9.

38. Mirshahi A, Roohipour R, Lashay A, Mohammadi S-F, Abdoallahi A, Faghihi H. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. *European journal of ophthalmology*. 2008 Jan 1;18(2):263-9.

39. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. *Retina (Philadelphia, Pa)*. 2006 Mar 1;26(3):275-8.

40. Huang Y-H, Yeh P-T, Chen M-S, Yang C-H, Yang C-M. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. *Retina (Philadelphia, Pa)*. 2009 Sep 1;29(8):1134-40.

41. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). *Retina (Philadelphia, Pa)*. 2006 Jan 1;26(9):1006-13.

42. Beutel J, Peters S, Lüke M, Aisenbrey S, Szurman P, Spitzer MS, et al. Bevacizumab as adjuvant for neovascular glaucoma. *Acta Ophthalmologica*. 2008 Sep 20.

43. Yeoh J, Williams C, Allen P, BATTERY R, Chiu D, Clark B, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. *Clin Experiment Ophthalmol*. 2008;36(5):449.

44. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. *Ophthalmology*. 2009 Oct 1;116(10):1943-8.

45. Adamis AP. Is diabetic retinopathy an inflammatory disease? *Br J Ophthalmol*. 2002 Apr 1;86(4):363-5.

46. Adamis AP, Shima DT. The role of vascular endothelial growth

factor in ocular health and disease. *Retina* (Philadelphia, Pa). 2005 Jan 1;25(2):111-8.

47. Felinski EA, Antonetti DA. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. *Curr Eye Res*. 2005 Nov 1;30(11):949-57.

48. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. *Eur J Pharmacol*. 1998 Jan 12;341(2-3):309-15.

49. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. *American Journal of Ophthalmology*. 1980 Dec 1;90(6):810-6.

50. Gillies MC, Sutter FKP, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. *Ophthalmology*. 2006 Sep 1;113(9):1533-8.

51. Karacorlu M, Ozdemir H, Karacorlu S, Alacali N. Regression of optic nerve head neovascularization in proliferative diabetic retinopathy after intravitreal triamcinolone. Regression of diabetic optic disc neovascularization after intravitreal triamcinolone. *Int Ophthalmol*. 2004 Mar 1;25(2):113-6.

52. Margolis R, Singh RP, Bhatnagar P, Kaiser PK. Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema. *Acta Ophthalmologica*. 2008 Feb 1;86(1):105-10.

53. Diabetes Control and Complications Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med*. 1993 Sep 30;329(14):977-86.

54. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*.

1998 Sep 12;352(9131):837-53.

55. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998 Sep 12;352(9131):854-65.

56. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. *BMJ*. 2008 Aug 26;337(aug261):a918-a.

57. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TME, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. *Lancet*. 2007 Nov 17;370(9600):1687-97.

58. PKC-DRS2 Study Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. *Ophthalmology*. 2006 Dec 1;113(12):2221-30.

59. Tamsma JT. Renal and retinal effects of enalapril and losartan in type 1 diabetes. *N Engl J Med*. 2009 Oct 1;361(14):1410; author reply 1.